期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗志贺毒素ⅡB亚单位单克隆抗体识别表位的初步鉴定 被引量：1

Elementary characterization on epitopes of anti-shiga toxinⅡB subunit monoclonal antibody
在线阅读 下载PDF
导出
摘要 目的初步确定抗志贺毒素ⅡB亚单位(Stx2B)单克隆抗体(McAb)1H9、1H10、3E5识别的抗原表位。方法运用DNAstar Protean软件,对Stx2B(1～72aa)全抗原进行表位预测;采用截短法分段构建重组质粒Stx2B50(23～72aa),Stx2B54(1～54aa)。用IPTG诱导表达融合蛋白。对表达产物进行SDS-PAGE蛋白电泳及Westernblot分析。结果1H9、1H10能够识别Stx2B和Stx2B50;3E5能够识别Stx2B、Stx2B50和Stx2B54。结论McAb1H9、1H10识别的抗原表位位于55～72aa,McAb3E5识别的抗原表位位于23～54aa。 Objective To identify the epitope domain of monoclonal antibody 1H9,1H10,and 3E5 against shiga toxin Ⅱ B subunit（Stx2B）. Methods The epitopes of Stx2B （1 -72 aa） were predicted by the DNAstar Protean software. The recombinant plasmids of Stx2B50 （23 -72 aa）, Stx2B54 （1 -54 aa） were constructed and then transformed to E. coli BL21 （ DE3 ） for expression under IPTG induction. The proteins were identified by SDS-PAGE and Western blotting. Results The monoclonal antibody 1H9 and 1Hi0 recognized antigen of Stx2B and Stx2B 50, while 3E5 recognized Stx2B, Stx2B50, and Stx2B54. Conclusion The epitope of mono- clonal antibody 1H9 and 1H10 is located at 55 -72 aa and the epitope of 3E5 is located at 23 -54 aa.
作者 陈洪章 曾浩 毛旭虎 罗萍 余抒 邹全明
机构地区 第三军医大学医学检验系临床微生物学及免疫学教研室
出处 《第三军医大学学报》 CAS CSCD 北大核心 2007年第19期1831-1833,共3页 Journal of Third Military Medical University
基金 国家高技术研究发展"863"计划(2006AA02Z405)~~
关键词 志贺毒素ⅡB亚基 抗原表位 鉴定 shiga toxin Ⅱ B subunit epitope identification
分类号 R392.12 [医药卫生—免疫学] R394.33 [医药卫生—医学遗传学]
  • 相关文献

参考文献12

  • 1Sandvig K. Shiga toxins[J]. Toxicon, 2001, 39( 11 ) : 1629 - 1635.
  • 2Mead S P, Slutsker L, Dietz V, et al. Food-related illness and death in the United States[J]. Emerg Infect Dis, 1999, 5(5) : 607 -625.
  • 3邹全明.肠出血性大肠杆菌O157感染防治研究进展[J].微生物学杂志,2004,24(5):96-98. 被引量：21
  • 4Watanabe M, Matsuoka K, Kita E, et al. Oral Therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections[J]. J Infect Dis, 2004, 189(3) : 360 -368.
  • 5Smith M J, Teel L D, Carvalho H M, et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2[J]. Vaccine, 2006, 24(19): 4122 -4129.
  • 6Tzipofi S, Sheoran A, Akiyoshi D, et al. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome [ J ]. Clin Microbiol Rev, 2004, 17(4) : 926 -941.
  • 7马颖,毛旭虎,邹全明,张卫军.肠出血性大肠杆菌O157∶H7志贺样毒素Ⅱ毒素亚单位Stx2A的表达与纯化[J].第三军医大学学报,2006,28(15):1582-1584. 被引量：2
  • 8Jameson B A, Wolf H. The antigenic index : a novel algorithm for predicting antigenic determinants[ J]. Comput Appl Biosci, 1988,4( 1 ) : 181 - 186.
  • 9奥斯伯FM，金斯顿RE，塞德曼JG，等．精编分子生物学实验指南[M]．马学军，舒跃龙，译．第4版．北京：科学出版社，2005：19-105．
  • 10O' Loughlin E V, Robins-Browne R M. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells[ J ]. Microbes Infect, 2001,3 (6) : 493 - 507.

二级参考文献19

  • 1周志江.肠出血性大肠杆菌O157[M].军事医学科学出版社出版,2002.50-51.
  • 2Konadu, -E-Y, etal. InvestigationalvaccineforEscherichiacoli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults[J]. The Journal of Infectious Diseases, 1998,177(2):383～ 387.
  • 3Slutsker. L, et al. Anationwide case- control study of Escherichia coli O157 infection in the United States[J]. The Journal of Infectious Diseases, 1998,177( 4 ): 962- 966.
  • 4Bell. B P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157 infections[ J ]. Pediatrics, 1997,100(1): E12.
  • 5Konadu,-E-Y, et al. Syntheses and Immunologic Properties of Escherichia coli O157 O-Specific Polysaccharide and Shiga Toxin 1 B SubunitConjugates in Mice[J]. Infection and Immunity, 1999,67(11): 6191-6193.
  • 6Pema NT, et al. Genome sequence of enterohaemorrhagic Escherichia coli O157[J]. Nature,2001,409(6819): 529- 533.
  • 7Hayashi T, et al. Complete genome sequence of enterohemorrhagic Escherichia coli O157 and genomic comparison with a laboratory strain K-12[J]. DNA Res,2001,8(1) :11-12.
  • 8Paola Marcato, et al. Immunoprophylactic Potential of Cloned Shiga Toxin 2 B Subunit[J]. The Journal of Infectious Diseases,2001,183(1) :435-443.
  • 9W. - G. Son et al. Immunological Characterization of Escherichia coli O157 Intiminγ1[J]. Clinical and Diagnostic Laboratory Immunology, 2002,9(1): 46-53.
  • 10ALEKSIC S,KARCH H,BOCKEMUHL J.A biotyping scheme for Shiga-like (Vero) toxin-producing Escherichia coli O157 and a list of serological cross-reactions between O157 and other gram-negative bacteria[J].Zentralbl Bakteriol,1992,276 (45):221-230.

共引文献26

同被引文献11

  • 1罗萍,邹全明,王晓勤,马颖.抗重组人表皮生长因子单克隆抗体的制备及生物学特性鉴定[J].免疫学杂志,2004,20(4):317-320. 被引量：8
  • 2马颖,毛旭虎,邹全明,张卫军.肠出血性大肠杆菌O157∶H7志贺样毒素Ⅱ毒素亚单位Stx2A的表达与纯化[J].第三军医大学学报,2006,28(15):1582-1584. 被引量：2
  • 3陈洪章,邹全明,罗萍,毛旭虎,曾浩,马颖,余抒,曾明.抗重组志贺毒素ⅡB亚基单克隆抗体的制备及生物学特性鉴定[J].免疫学杂志,2007,23(2):148-151. 被引量：4
  • 4徐志凯.实用单克隆技术[M].西安:陕西科学技术出版社,1992.274-287.
  • 5Wong C S,Jelacic S,Habeeb R L,et al.The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coil O157:H7 iofections[J].N Engl J Med,2000,342(26):1930-1936.
  • 6奥斯伯 F,布伦特 E,金斯顿 R E,等.精编分子生物学实验指导[M].颜子颖,王海林,译.北京:科学出版社,1999:366-373.
  • 7Fraser M E,Fujinaga M,Chemey M M,et al.Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7[J].J Biol Chem,2004,279(26):27511-27517.
  • 8Sheoran A S,Chapman S,Singh P,et al.Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escheriehia coli expressing Stx2 variants[J].Infaet Immun,2003,71(6):3125-3130.
  • 9Nishikawa K,Matsuoka K,Kita E,et al.A therapeutic agent with oriented carbohydrates for treatment of infeetions by Shiga toxin-producing Escherichia coli O157:H7[J].Proc Natl Acad Sci U S A,2002,99 (11):7669-7674.
  • 10Wen S X,Teel L D,Judge N A,et al.A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2[J].Proe Nail Acad Sci U S A,2006,103(18):7082 -7087.

引证文献1

二级引证文献2

第三军医大学学报
2007年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部